TNF gene polymorphisms are associated with reduced survival in severe Chagas' disease cardiomyopathy patients

Sandra A Drigo1, Edecio Cunha-Neto, Bárbara Ianni

  • 1Heart Institute (InCor), School of Medicine, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar 44, bloco 2, 9 andar, CEP: 05403-001 São Paulo, Brazil.

Microbes and Infection
|January 24, 2006
PubMed

Insights

Genetic factors influence survival in Chronic Chagas' disease cardiomyopathy (CCC). Specific tumor necrosis factor (TNF) gene variations are linked to significantly reduced survival in severe CCC patients, impacting mortality predictions.

Area of Science:

  • Cardiology
  • Genetics
  • Infectious Diseases

Background:

  • Chronic Chagas' disease cardiomyopathy (CCC) is a severe complication of Trypanosoma cruzi infection, leading to heart failure and reduced survival.
  • Genetic factors may explain differential survival rates among severe CCC patients.
  • Tumor necrosis factor-alpha (TNF-alpha) is implicated in heart failure progression and is elevated in CCC patients.

Purpose of the Study:

  • To investigate the role of tumor necrosis factor (TNF) gene polymorphisms as predictors of mortality in severe Chronic Chagas' disease cardiomyopathy (CCC).

Main Methods:

  • Genotyping of the TNFa microsatellite and the -308 TNF promoter polymorphism in 42 severe CCC patients.
  • Survival analysis using Cox proportional hazards model to assess the impact of TNF genotypes on mortality.

Main Results:

  • The TNF genotype, specifically the TNF2 promoter allele or TNFa2 microsatellite allele, was identified as an independent predictor of mortality in severe CCC.
  • Patients with TNF2 or TNFa2 alleles had significantly shorter median survival times (2.9 and 8 months, respectively) compared to other alleles (HR(adj)=2.28, p=0.020).

Conclusions:

  • This study identifies a genetic factor (TNF genotype) associated with reduced survival in severe Chronic Chagas' disease cardiomyopathy.
  • The findings suggest that TNF genotype should be considered in therapeutic planning for severe CCC patients to predict mortality risk.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
American Trypanosomiasis01:22

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...